# MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
Canonical URL: https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-last-patient-last-visit-in-the-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast
Ticker: MNOV
Company: MediciNova
Source: MediciNova
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.medicinova.com
## Summary

LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2

## Article Body
LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2
## Recent Company News
- 2026-06-30 12:00 EST — [MediciNova CEO Provides Shareholder Update](https://biopharmsignal.com/news/MNOV/medicinova-ceo-provides-shareholder-update-9776ffac) — Source: MediciNova
- 2026-06-25 13:46 EST — [MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment](https://biopharmsignal.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-use-of-mn-166-in-combination-with-anti-pd-1-immune-checkpoint-inhibitor-for-glioblastoma-treatment) — Source: MediciNova
- 2026-06-25 13:46 EST — [MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)](https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-last-patient-last-visit-in-the-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast) — Source: MediciNova
- 2026-06-25 13:46 EST — [MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)](https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-patient-enrollment-in-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast) — Source: MediciNova
- 2026-06-25 13:46 EST — [MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards](https://biopharmsignal.com/news/MNOV/medicinova-wins-contract-research-and-development-innovation-award-at-2025-biotech-breakthrough-awards) — Source: MediciNova
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)